Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
MJ van den Bent, AA Brandes, R Rampling… - Journal of Clinical …, 2009 - ascopubs.org
Purpose Approximately 50% of glioblastomas (GBMs) are characterized by overexpression
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …
[PDF][PDF] " Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
MJ van den Bent, JF Baurain, AA Brandes… - J Clin …, 2009 - dial.uclouvain.be
ABSTRACT Purpose: Approximately 50% of glioblastomas (GBMs) are characterized by
overexpression of the epidermal growth factor receptor (EGFR) and EGFR gene …
overexpression of the epidermal growth factor receptor (EGFR) and EGFR gene …
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
MJ van den Bent, AA Brandes… - Journal of clinical …, 2009 - pubmed.ncbi.nlm.nih.gov
Purpose Approximately 50% of glioblastomas (GBMs) are characterized by overexpression
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …
[HTML][HTML] Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
MJ van den Bent, AA Brandes, R Rampling… - Journal of Clinical …, 2009 - ncbi.nlm.nih.gov
Purpose Approximately 50% of glioblastomas (GBMs) are characterized by overexpression
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
M van den Bent, A Brandes, R Rampling… - Journal of Clinical …, 2009 - repub.eur.nl
Purpose Approximately 50% of glioblastomas (GBMs) are characterized by overexpression
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
MJ van den Bent, AA Brandes, R Rampling… - Journal of Clinical …, 2009 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Approximately 50% of glioblastomas
(GBMs) are characterized by overexpression of the epidermal growth factor receptor (EGFR) …
(GBMs) are characterized by overexpression of the epidermal growth factor receptor (EGFR) …
[引用][C] Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
MJ VAN DEN BENT, AA BRANDES… - Journal of clinical …, 2009 - pascal-francis.inist.fr
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent
Glioblastoma : EORTC Brain Tumor Group Study 26034 CNRS Inist Pascal-Francis CNRS …
Glioblastoma : EORTC Brain Tumor Group Study 26034 CNRS Inist Pascal-Francis CNRS …
[PDF][PDF] Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
MJ van den Bent, AA Brandes, R Rampling… - J Clin …, 2009 - researchgate.net
Purpose Approximately 50% of glioblastomas (GBMs) are characterized by overexpression
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
MJ van den Bent, AA Brandes, R Rampling… - Journal of Clinical …, 2009 - europepmc.org
Purpose Approximately 50% of glioblastomas (GBMs) are characterized by overexpression
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
MJ van den Bent, AA Brandes… - Journal of …, 2009 - researchinformation.amsterdamumc …
PURPOSE: Approximately 50% of glioblastomas (GBMs) are characterized by
overexpression of the epidermal growth factor receptor (EGFR) and EGFR gene …
overexpression of the epidermal growth factor receptor (EGFR) and EGFR gene …